Literature DB >> 17989711

Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.

H Tamai, Y Shioi, H Yamaguchi, M Okabe, S Wakita, T Mizuki, K Nakayama, K Inokuchi, K Tajika, K Dan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17989711     DOI： 10.1038/sj.leu.2405029

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Hirotaka Takasaki; Ayumi Numata; Shin Fujisawa; Atsuo Maruta; Hiroshi Harada; Hiraku Mori; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2011-12-02       Impact factor: 2.490

2.  Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.

Authors:  Masahiko Sumi; Naoaki Ichikawa; Kentaro Nasu; Ikuo Shimizu; Toshimitsu Ueki; Mayumi Ueno; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2009-11-11       Impact factor: 2.490

Review 3.  Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Authors:  Laurène Fenwarth; Elise Fournier; Meyling Cheok; Thomas Boyer; Fanny Gonzales; Sylvie Castaigne; Nicolas Boissel; Juliette Lambert; Hervé Dombret; Claude Preudhomme; Nicolas Duployez
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.